Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Milestone income increased from 6 cases in the prior-year period to 10, an increase of ¥4,835 million. Sales of Vyepti® and Quviviq® remained strong. Research and development expenses decreased due to progress in multiple clinical development programs and a greater focus on development areas, while selling, general and administrative expenses decreased as a result of cost reductions.
None (no applicable matters)
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥27,742 million (YoY +27.0%) |
| Operating profit | ¥3,175 million |
| Ordinary income | ¥2,565 million |
| Profit attributable to owners of the parent | ¥2,328 million |
| Net income per share | ¥25.61 |
| Equity ratio | End of the current fiscal period 49.3 / End of previous period 45.3 |
| Total assets | ¥130,252 million |
| Net assets | ¥64,153 million |
| Cash flows from operating activities | ¥5,728 million |
| Cash flows from investing activities | ¥-4,218 million |
| Cash flows from financing activities | ¥-5,043 million |
| Cash and cash equivalents at end of period | ¥16,613 million |
| Full-year earnings forecast | Net Sales Downside floor ¥33,800 million / Limit ¥48,800 million / Year-on-year change 14.1%〜64.8% / Operating profit Downside floor ¥700 million / Limit ¥15,700 million / Year-on-year change Not disclosed / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | 0 Yen → 0 Yen |
| Depreciation and amortization | ¥1,254 million |
| Impairment loss | ¥1,717 million |
| Disclosure regarding the going concern assumption | None (no applicable matters) |
| Change in accounting policy | Changes due to revisions to standards None / Other changes No (changes in presentation are disclosed separately) / Change in accounting estimate None / Restatement Not disclosed |
| Changes in the scope of consolidation | No (0 additions, 0 exclusions) |
| Material subsequent events | Approval of the issuance of performance-linked stock options for 3 executive officers and execution of an exclusive license agreement for lucerastat in Japan and certain parts of the Asia-Pacific region. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (scheduled to be held online; attendees not specified) |
| Issued Shares at Period-End | 92,615,359 |
| Treasury Shares at Period-End | 1,224,044 |
| Factors Behind Changes in Business Performance | Milestone income increased from 6 cases in the prior-year period to 10, an increase of ¥4,835 million. Sales of Vyepti® and Quviviq® remained strong. Research and development expenses decreased due to progress in multiple clinical development programs and a greater focus on development areas, while selling, general and administrative expenses decreased as a result of cost reductions. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in profit was driven by milestone income increasing from 6 cases in the prior-year period to 10, strong sales of Vyepti® and Quviviq®, and decreases in research and development expenses and selling, general and administrative expenses.